http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0976745-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44c713790ce00813da2e6c6d57a29456 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 |
| filingDate | 1998-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2003-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18e21fcccde436e9d62f1b753edcddee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53017299c7b37e7d7ec0fec17a32c5a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c099e5f571543b9573f8184923e8ea1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab87c51956d8567daa33c0172a4d4396 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2a91d18ea70a546d92af6b9a66f390d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe83e3fadcac6c54d7aa9ba248a806e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58c954e8aff2d830d4133d75b05dfe0a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db031cc4ac0d7e9941f9d939b55cd786 |
| publicationDate | 2003-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0976745-B1 |
| titleOfInvention | 4-tetrahydropyridylpyrimidine derivatives |
| abstract | A 4-tetrahydropyridylpyrimidine derivative represented by formula (I): <CHEM> wherein Ar represents a phenyl group substituted with 1 to 3 substituents selected from a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, and a trifluoromethyl group, a phenyl group, a thienyl group or a furanyl group; R<1> represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms; R<2> represents an alkyl group having 1 to 5 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms, an alkenyl group having 2 to 5 carbon atoms or an alkynyl group having 2 to 5 carbon atoms; and X<1>, X<2>, and X<3>, which may be the same or different, each represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms, or a pharmaceutically acceptable salt thereof. The invention provides a compound effective on diseases which CRF is considered to participate in, such as depression, anxiety, Alzheimer's disease, Parkinson's syndrome, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head wounds, inflammation, and immunity-associated diseases. |
| priorityDate | 1997-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 237.